139 related articles for article (PubMed ID: 30592555)
21. Lumican: a new inhibitor of matrix metalloproteinase-14 activity.
Pietraszek K; Chatron-Colliet A; Brézillon S; Perreau C; Jakubiak-Augustyn A; Krotkiewski H; Maquart FX; Wegrowski Y
FEBS Lett; 2014 Nov; 588(23):4319-24. PubMed ID: 25304424
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody.
Razai AS; Eckelman BP; Salvesen GS
J Biol Chem; 2020 Feb; 295(8):2464-2472. PubMed ID: 31953328
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
25. Substrate derived sequences act as subsite-blocking motifs in protease inhibitory antibodies.
Choe H; Antee T; Ge X
Protein Sci; 2023 Jul; 32(7):e4691. PubMed ID: 37278099
[TBL] [Abstract][Full Text] [Related]
26. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
27. Engineering the S1' subsite of trypsin: design of a protease which cleaves between dibasic residues.
Kurth T; Grahn S; Thormann M; Ullmann D; Hofmann HJ; Jakubke HD; Hedstrom L
Biochemistry; 1998 Aug; 37(33):11434-40. PubMed ID: 9708978
[TBL] [Abstract][Full Text] [Related]
28. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.
Kola A; Baensch M; Bautsch W; Hennecke M; Klos A; Casaretto M; Köhl J
Immunotechnology; 1996 Jun; 2(2):115-26. PubMed ID: 9373320
[TBL] [Abstract][Full Text] [Related]
29. Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity.
Maola K; Wilbs J; Touati J; Sabisz M; Kong XD; Baumann A; Deyle K; Heinis C
Angew Chem Int Ed Engl; 2019 Aug; 58(34):11801-11805. PubMed ID: 31251434
[TBL] [Abstract][Full Text] [Related]
30. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
32. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
Fray MJ; Burslem MF; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
[TBL] [Abstract][Full Text] [Related]
33. Probing the serpin structural-transition mechanism in ovalbumin mutant R339T by proteolytic-cleavage kinetics of the reactive-centre loop.
Arii Y; Hirose M
Biochem J; 2002 Apr; 363(Pt 2):403-9. PubMed ID: 11931671
[TBL] [Abstract][Full Text] [Related]
34. MMP-14 degrades tropoelastin and elastin.
Miekus N; Luise C; Sippl W; Baczek T; Schmelzer CEH; Heinz A
Biochimie; 2019 Oct; 165():32-39. PubMed ID: 31278967
[TBL] [Abstract][Full Text] [Related]
35. Simple modifications of the serpin reactive site loop convert SCCA2 into a cysteine proteinase inhibitor: a critical role for the P3' proline in facilitating RSL cleavage.
Luke C; Schick C; Tsu C; Whisstock JC; Irving JA; Brömme D; Juliano L; Shi GP; Chapman HA; Silverman GA
Biochemistry; 2000 Jun; 39(24):7081-91. PubMed ID: 10852705
[TBL] [Abstract][Full Text] [Related]
36. Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis.
Holtz B; Cuniasse P; Boulay A; Kannan R; Mucha A; Beau F; Basset P; Dive V
Biochemistry; 1999 Sep; 38(37):12174-9. PubMed ID: 10508422
[TBL] [Abstract][Full Text] [Related]
37. Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate.
Chang JY
Eur J Biochem; 1985 Sep; 151(2):217-24. PubMed ID: 2863141
[TBL] [Abstract][Full Text] [Related]
38. NMR determination of pKa values for Asp, Glu, His, and Lys mutants at each variable contiguous enzyme-inhibitor contact position of the turkey ovomucoid third domain.
Song J; Laskowski M; Qasim MA; Markley JL
Biochemistry; 2003 Mar; 42(10):2847-56. PubMed ID: 12627950
[TBL] [Abstract][Full Text] [Related]
39. Generation of highly selective monoclonal antibodies inhibiting a recalcitrant protease using decoy designs.
Lee KB; Dunn ZS; Lopez T; Mustafa Z; Ge X
Biotechnol Bioeng; 2020 Dec; 117(12):3664-3676. PubMed ID: 32716053
[TBL] [Abstract][Full Text] [Related]
40. Renaissance of MMPs as therapeutic targets? Maybe.
Goldberg GI
Structure; 2015 Jan; 23(1):6-7. PubMed ID: 25565101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
